Malaria is the world's most important parasitic disease, imposing a massive health burden on
people living in the tropics, often in the poorest countries. The vast majority of deaths in humans
from malaria are caused by one species of the hemoprotozoan,
Plasmodium falciparum., against
which effective control measures are urgently needed. The global situation has deteriorated in
recent times due to increased resistance of the anopheline mosquitoes that transmit
P. falciparum
to insecticides, and of the parasites themselves to drug therapy. An efficacious and cost-effective
vaccine against this parasite is considered a public health priority. A vaccine that targets
pre-erythrocytic parasites in the liver could potentially prevent clinical disease by blocking
development of the pathogenic erythrocytic stage of the parasite's life cycle. Among around 40
known
P. falciparum antigens, liver stage antigen-1 (LSA-1) is the only protein expressed
exclusively by liver stage parasites. Independent studies in humans have consistently related
immune responses to LSA-1 with resistance to malaria infection or disease, providing a powerful
rationale for the development of liver stage vaccines based on LSA-1. By dissecting the
mechanism(s) of immunity to this antigen, epitopes associated with protection can be evaluated
in different delivery systems as components of a focused and coordinated multi-antigen malaria
vaccine strategy.
View full abstract